A Real-World Data-Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B-Cell Lymphoma Patients.

Jelena JelicicKaren Juul-JensenZoran BukumiricMikkel Runason SimonsenMichael Roost ClausenAhmed Ludvigsen Al-MashhadiRobert Schou PedersenChristian Bjørn PoulsenAnne Ortved GangPeter BrownTarec Christoffer El-GalalyThomas Stauffer Larsen

Published in: European journal of haematology (2024)

True low-risk patients are more optimal identified by NCCN-IPI and should be excluded from front-line clinical trials due to their excellent prognosis. However, additional high-risk factors besides clinical prognostic models need to be considered when selecting trial-eligible patients.

Keyphrases

end stage renal disease
clinical trial
diffuse large b cell lymphoma
newly diagnosed
ejection fraction
chronic kidney disease
risk factors
prognostic factors
randomized controlled trial
study protocol
big data
open label